Life Sciences

  • October 15, 2026

    OrbiMed Closes 2 Latest Funds With Combined $3B In Tow

    Healthcare-focused investment firm OrbiMed on Thursday revealed that it has secured $3 billion of investor commitments across its two latest private equity funds.

  • October 15, 2026

    Medical AI Platforms Report Settlement Amid Discovery Battle

    Medical artificial intelligence startup OpenEvidence and competitors Doximity Inc. and Pathway Medical Inc. told a Massachusetts federal judge on Thursday that they have reached a settlement in principle to resolve a contentious lawsuit and counterclaim.

  • October 15, 2026

    PhRMA Again Seeks To Join 340B Rebate Pilot Fight

    The Pharmaceutical Research and Manufacturers of America on Thursday asked a Maine federal court to let it join a lawsuit challenging the Trump administration's proposed rebate system in the 340B drug discount program, arguing the litigation could directly affect its members' approved plans and financial interests.

  • October 15, 2026

    For 2nd Time, PTAB Won't Invalidate Claims In DNA Patent

    The Patent Trial and Appeal Board has once again found that Guardant Health couldn't show that claims in a University of Washington DNA sequencing patent that had been part of a $245 million infringement judgment were invalid.

  • October 15, 2026

    Calif. Pot Shop Escapes Suit Over Alleged Gummy Reaction

    A California appeals court threw out a man's fraud and unfair competition claims against a cannabis dispensary that sold him a gummy he said induced a panic attack, saying his complaint fails to indicate the dispensary or its employee knowingly misled him.

  • October 14, 2026

    Boies Schiller Adds Ex-DOJ Civil Division Leader In NY, DC

    Boies Schiller Flexner LLP has added a former deputy assistant attorney general in the U.S. Department of Justice's Civil Division to its global investigations and white collar teams in New York and Washington, D.C., according to an announcement made Wednesday.

  • October 14, 2026

    10th Circ. Backs Asset Freeze In SEC Case Against Biotech

    The Tenth Circuit on Wednesday backed a lower court's order freezing a biotech firm's assets in a suit brought by the U.S. Securities and Exchange Commission accusing the company and its founders of misappropriating roughly $9 million.

  • October 14, 2026

    Genentech Wins Judge's OK Of $18M Novartis Award

    A D.C. federal judge has enforced a nearly $18 million arbitral award against Novartis Pharma AG following its dispute with biotechnology firm Genentech Inc. over a licensing agreement for an eye medication.

  • October 14, 2026

    Cannabis Reform Foes Cite GAO In Push To Reopen Hearings

    A U.S. Drug Enforcement Administration administrative law judge on Wednesday ordered the government to respond to a bid by opponents of cannabis reform to reopen hearings on a proposal to loosen federal restrictions on marijuana.

  • October 14, 2026

    Anthropic Seeks To Dodge AI Patent Suit From U. of Tenn.

    Anthropic says it shouldn't have to face a lawsuit accusing it of infringing a pair of patents related to neural networks owned by a research arm of the University of Tennessee because its Claude artificial intelligence tool isn't covered by the patents.

  • October 14, 2026

    LG Says It Doesn't Owe Insurer For Range Fire Damage

    LG Electronics USA Inc. doesn't owe an insurer for coverage it paid to a pair of homeowners after the cooktop burner on their LG electric range allegedly caused a fire, LG said in an answer to an insurer complaint removed to North Carolina federal court.

  • October 14, 2026

    Fed. Circ. Won't Revive UPL Patent, But Rejects Sanctions

    The Federal Circuit on Wednesday refused to bring back an agricultural fungicide patent owned by UPL Ltd. that was invalidated at the Patent Trial and Appeal Board, but also shot down a bid to sanction the Indian agrochemicals company.

  • October 14, 2026

    Sanofi Agrees Not To Disparage Rival's Flu Vaccine

    European enforcers have accepted commitments from Sanofi over concerns that it blocked competition from a rival flu vaccine for vulnerable patients by making disparaging statements to healthcare professionals in Germany and France.

  • October 13, 2026

    Liquidia Settles United Therapeutics Suits With $380.7M Deal

    Liquidia will pay out $380.7 million as part of a settlement agreement with United Therapeutics Corp. that resolves six lawsuits between the pharmaceutical companies, Liquidia announced Tuesday, saying patients will continue to have access to its Yutrepia lung disease treatment that was central to litigation.

  • October 13, 2026

    Skadden Adds 5 DLA Piper Mass Torts Attys To Chicago Office

    Skadden Arps Slate Meagher & Flom LLP continues to grow its mass torts and products liability litigation offerings in its Chicago office with the addition of five veteran litigators from DLA Piper, the firm announced on Tuesday.

  • October 13, 2026

    Biotech Co.'s Egg Protein Patent Case Flops In Del. Court

    A Delaware federal judge found cracks in a biotechnology company's jurisdictional arguments in a case it brought seeking a declaration that it wasn't infringing a rival's patent covering animal-free egg protein, ruling Friday there was no imminent controversy between the companies when the lawsuit was filed.

  • October 13, 2026

    FTC Wants Shkreli Sanctioned Over Pharma Industry Ban

    The Federal Trade Commission and seven states asked a New York federal judge Tuesday to hold Martin Shkreli in contempt for violating a court order banning him from the pharmaceutical industry by trading in industry stocks and broadcasting opinions about the business since he was released from prison in 2022.

  • October 13, 2026

    Corcept Looks To End Teva's Mifepristone Antitrust Case

    Corcept Therapeutics told a California federal court there's no evidence that it blocked generic competition for its cortisol disorder treatment Korlym, urging the court to toss an antitrust case from Teva Pharmaceuticals ahead of trial.

  • October 13, 2026

    Fed. Circ. Backs L'Oreal's Alice Win On Face Analysis Patent

    The Federal Circuit on Tuesday issued a one-word order affirming a California federal court's invalidation of a facial measurement and analysis patent that had been asserted against the cosmetic giant L'Oreal USA Inc.

  • October 13, 2026

    Judge Finds Cyanide Antidote Generic Infringes IP After Trial

    A Delaware federal judge ruled Tuesday that a generic version of a cyanide antidote was infringing three patents asserted by Hope Medical Enterprises after a bench trial where Accord Healthcare Inc. claimed its product did not infringe and that the patents were invalid.

  • October 13, 2026

    Groups Ask Justices To Hear Apple's ITC Industry Rule Fight

    The Federal Circuit wrongly continued the degradation of the U.S. International Trade Commission's domestic industry requirement in patent disputes by sustaining a decision that Apple Watches infringe Masimo Corp.'s patents, groups supporting Apple's petition told the U.S. Supreme Court on Tuesday.

  • October 13, 2026

    Jones Day, Morgan Lewis Guide $2.1B Steris-Xodus Deal

    Steris PLC has agreed to acquire specialty surgical products business Xodus Medical Inc. and some affiliates for $2.1 billion, with Jones Day advising Steris and Morgan Lewis & Bockius LLP representing Xodus.

  • October 13, 2026

    Troutman Grows Life Sciences Litigation Group In Philly, NY

    A pair of attorneys specializing in healthcare and life sciences litigation recently moved their practices to Troutman Pepper Locke LLP's offices in Philadelphia and New York City.

  • October 13, 2026

    1st Circ. Revives Amgen Migraine Drug Risk Label Suit

    A mother in Massachusetts is entitled to pursue a new theory of liability against drugmaker Amgen Inc. over the death of her 25-year-old son after he took the company's then-recently approved migraine medication Aimovig in 2018, the First Circuit has found.

  • October 13, 2026

    Haynes Boone Launches In San Diego For 4th Calif. Location

    Haynes Boone has opened its first San Diego office to deepen its life sciences, healthcare and technology capabilities and has selected a co-chair of its biotechnology practice to lead its fourth workplace in California.

Expert Analysis

  • Vanda Ruling Offers New Guide To Generic Labeling Disputes

    Author Photo

    The D.C. Circuit's recent decision in Vanda Pharmaceuticals v. U.S. Food and Drug Administration is significant for its guidance on when generic-drug labeling remains sufficiently similar to brand labeling and when a difference requires a statutory exception, says Shashank Upadhye at Upadhye Tang.

  • Attorneys Using AI May Have Ethical Duty To Redact Docs

    Author Photo

    The trajectory of legal ethics guidance in recent years strongly suggests that as redaction technology becomes more accessible, the failure to use it when uploading highly confidential materials into artificial intelligence tools will become increasingly difficult to defend as reasonable, say attorneys at Lewis Brisbois.

  • Cannabis, Psychedelics Boom Raises IP Hurdles

    Author Photo

    Recent data regarding patent filing activity and litigation in the cannabis and psychedelics markets indicates that as commercial interest accelerates, the scope of publicly accessible prior art is also expanding, setting a higher bar for novelty and nonobviousness in patent applications, say attorneys at Sterne Kessler.

  • State AI Safety Laws Raise New Liabilities For Healthcare Cos.

    Author Photo

    Healthcare and life science companies using third-party artificial intelligence tools should pay particular attention to the changing state-level legal landscape, where the rollout of multiple AI safety laws is introducing both new compliance obligations and potential consumer protection liabilities, say attorneys at McDermott.

  • Series

    Juggling And Unicycling Make Me A Better Lawyer

    Author Photo

    Because I juggle (sometimes with fire) and ride the unicycle, friends and family used to joke that I should join the circus, but I pursued the practice of law instead and learned that my hobbies benefit my profession in several important ways, says Morgan Eddy at Smith Currie.

  • AI Note-Taking Suits May Fill Gap In Privacy Law Structure

    Author Photo

    A recent class action against Granola joins other pending lawsuits against AI note-taking providers, highlighting the legal uncertainty surrounding these tools, but there are practical steps companies using "invisible" AI services can take to mitigate risk, including conducting inventories and reviewing access permissions, say attorneys at Barnes & Thornburg.

  • FDA Closeout Letter Suggests Relaxing Stance On Wearables

    Author Photo

    The U.S. Food and Drug Administration's recent decision not to pursue enforcement action against Whoop's wearable blood pressure tracker, read together with guidance released earlier this year, suggests a softer shift in the FDA's approach to regulating wearables, say attorneys at Arnold & Porter.

  • Fed. Circ. Dental IP Ruling Reinforces Prior Art Framework

    Author Photo

    The Federal Circuit's recent decision in Dental Monitoring v. Align Technology reaffirms the necessity of substantive written description support for establishing an earlier effective prior art date under the America Invents Act, and aligns Patent Trial and Appeal Board practice with district court litigation, say attorneys at Morgan Lewis.

  • Justices' Hikma Reasoning May Extend Well Beyond Pharma

    Author Photo

    The active steps framework announced by the U.S. Supreme Court in its Hikma v. Amarin decision, finding that Amarin failed to plausibly allege inducement of infringement, has the potential to reshape how courts evaluate inducement claims across patent, copyright and other doctrines, say attorneys at BCLP.

  • Teva MDL Loss Shows DPAs Can Return To Haunt Civil Suits

    Author Photo

    Teva’s recent partial summary judgment loss in antitrust multidistrict litigation reinforces the importance of carefully scrutinizing any statement of facts a company admits to in a deferred prosecution agreement, and illustrates the potential costs of resolving a criminal investigation this way, say attorneys at Sheppard.

  • An Inside Look At Squires' Discretionary Denials

    Author Photo

    A deep dive into the discretionary denials issued by U.S. Patent and Trademark Office Director John Squires since he took over last year identifies trends in commonly asserted arguments and how they correlate with institution outcomes, say attorneys at Kirkland & Ellis.

  • Series

    Ballet Makes Me A Better Lawyer

    Author Photo

    A lifetime of learning and performing ballet taught me that success — whether in dance or practicing law — comes only through hours of thorough preparation, boundless energy and relentless effort, says Sharon Katz-Pearlman at Greenberg Traurig.

  • Fed. Circ. In July: Meeting The Enablement Requirement

    Author Photo

    The Federal Circuit's decision in Wyeth v. AstraZeneca last month exemplifies when a generalized conception of an invention is insufficient to enable the full scope of asserted patent infringement claims, and may lead to more enablement challenges, say attorneys at Knobbe Martens.

  • Series

    Taekwondo Makes Me A Better Lawyer

    Author Photo

    Taekwondo has taught me to recognize when to fight for a position and when to focus on finding a solution, and that the best outcomes are often achieved by solving problems — all of which has improved my work as a bankruptcy lawyer, mediator and Subchapter V trustee, says Amy Denton Mayer at Berger Singerman.

  • Why AI Diligence Is Especially Key In IP Practice

    Author Photo

    In light of recent federal court sanctions against intellectual property litigators for filing work product generated by artificial intelligence without verification, it's important to consider the unique risks and consequences that can arise from overreliance on AI, which poses less visible risks in IP matters, says Stephen Ball at Husch Blackwell.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.